ZA201802256B - Compounds and therapeutic uses thereof - Google Patents

Compounds and therapeutic uses thereof

Info

Publication number
ZA201802256B
ZA201802256B ZA2018/02256A ZA201802256A ZA201802256B ZA 201802256 B ZA201802256 B ZA 201802256B ZA 2018/02256 A ZA2018/02256 A ZA 2018/02256A ZA 201802256 A ZA201802256 A ZA 201802256A ZA 201802256 B ZA201802256 B ZA 201802256B
Authority
ZA
South Africa
Prior art keywords
compounds
therapeutic uses
therapeutic
Prior art date
Application number
ZA2018/02256A
Other languages
English (en)
Inventor
Christopher Pickford
Christine Watson
Melanie Glossop
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of ZA201802256B publication Critical patent/ZA201802256B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)
  • Central Air Conditioning (AREA)
ZA2018/02256A 2015-10-08 2018-04-06 Compounds and therapeutic uses thereof ZA201802256B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof
PCT/GB2016/053134 WO2017060729A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ZA201802256B true ZA201802256B (en) 2019-01-30

Family

ID=55130801

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/02256A ZA201802256B (en) 2015-10-08 2018-04-06 Compounds and therapeutic uses thereof

Country Status (10)

Country Link
US (2) US10953100B2 (enExample)
EP (1) EP3359201A1 (enExample)
JP (1) JP7065775B2 (enExample)
CN (1) CN108472381B (enExample)
AU (1) AU2016335365B2 (enExample)
CA (1) CA3001084A1 (enExample)
GB (1) GB201517859D0 (enExample)
IL (1) IL258511B (enExample)
WO (2) WO2017060728A1 (enExample)
ZA (1) ZA201802256B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707076D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
JP7185622B2 (ja) * 2016-09-13 2022-12-07 センタウリ セラピューティクス リミテッド 新規化合物及びその治療上の使用
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705684D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201707079D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN111748089B (zh) * 2019-03-28 2023-07-18 成都先导药物开发股份有限公司 一种生物素标记化合物以及确定化合物结合靶标蛋白的方法
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP1534324B1 (en) * 2002-08-20 2019-01-16 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
WO2005014008A2 (en) * 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US8604184B2 (en) * 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity
US9636419B2 (en) * 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting
GB201411150D0 (en) 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof

Also Published As

Publication number Publication date
NZ741118A (en) 2024-07-26
US10953100B2 (en) 2021-03-23
IL258511A (en) 2018-06-28
US20210369850A1 (en) 2021-12-02
CN108472381A (zh) 2018-08-31
IL258511B (en) 2021-10-31
AU2016335365B2 (en) 2021-12-09
JP2018531287A (ja) 2018-10-25
GB201517859D0 (en) 2015-11-25
JP7065775B2 (ja) 2022-05-12
AU2016335365A1 (en) 2018-04-26
US20180280521A1 (en) 2018-10-04
EP3359201A1 (en) 2018-08-15
CN108472381B (zh) 2023-06-06
WO2017060729A1 (en) 2017-04-13
CA3001084A1 (en) 2017-04-13
WO2017060728A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
GB201403093D0 (en) Therapeutic compounds and their use
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
EP3204360A4 (en) Therapeutic compounds and uses thereof
SG11201706029VA (en) Anti-senescence compounds and uses thereof
IL258997B (en) Therapeutic composition of cannabinoid and honey
ZA201802256B (en) Compounds and therapeutic uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
GB201502412D0 (en) Therapeutic use
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
GB201608797D0 (en) Therapeutic use
GB201504763D0 (en) Compounds and uses
IL265269B (en) New compounds and their medicinal uses
GB201418809D0 (en) Therapeutic agents and uses thereof
IL253459B (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB201506786D0 (en) Therapeutic use
IL257737B (en) Medical compounds based on methanopyrrolo-pyridine-carboxylate and their synthesis
GB201615560D0 (en) Novel compounds and therapeutic uses thereof
GB2543375B (en) Compounds and their uses
HK1259593A1 (en) Compounds and therapeutic uses thereof
GB201417777D0 (en) Novel compounds and therapeutic uses thereof